Home/Innosphera Pharma/Lyne Gagnon

LG

Lyne Gagnon

Chief Scientific Officer

Innosphera Pharma

Therapeutic Areas

Pulmonary Fibrosis Inflammatory Diseases Metabolic Disorders

Innosphera Pharma Pipeline

Drug	Indication	Phase
ING-006	Idiopathic Pulmonary Fibrosis	Preclinical
ING-008	Cardiometabolic (Obesity, MASH)	Preclinical
ING-Series	Various cardiometabolic and chronic inflammatory conditions	Preclinical

Leadership Team at Innosphera Pharma

Executive Chairman

François Ravenelle

President and CEO

Chief Medical Officer (fractional)

View full Innosphera Pharma profile